Naloxone does not modify fenfluramine‐induced prolactin increase in obese patients

Argenio, G. F.; Bernini, Giampaolo; Vivaldi, M. S.; Corso, C. Del; Santoni, R.; Franchi, F

doi:10.1111/j.1365-2265.1991.tb00935.x

Cited by 6 publications

(3 citation statements)

References 30 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, healthy obese subjects have decreased prolactin responses to insulin‐induced hypoglycaemia and TRH stimulation (Donders et al ., 1985; Weaver et al ., 1990). Impairment of the serotoninergic (Bernini et al ., 1989; Pijl et al ., 1993) and the opioidergic (Argenio et al ., 1991) pathways have been implicated in this impaired modulation of prolactin release.…”

Section: Discussionmentioning

confidence: 99%

Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels

Greenman

Tordjman

Stern

1998

Clinical Endocrinology

203

162

View full text Add to dashboard Cite

Weight gain and elevated body weight are frequently associated with prolactinomas regardless of a mass effect on the hypothalamus or pituitary function. In this series, weight loss was recorded in 70% of prolactinomas patients and in 90% of male patients who normalized their prolactin levels. We propose the inclusion of hyperprolactinaemia in the differential diagnosis of endocrine obesity and weight gain.

show abstract

Section: Discussionmentioning

confidence: 99%

Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels

Greenman

Tordjman

Stern

1998

Clinical Endocrinology

203

162

View full text Add to dashboard Cite

show abstract

“…25,26 Furthermore, naloxone does not alter the fen¯uramine-enhanced prolactin response to TRH, suggesting that the prolactin alterations are not the result of an interaction between central opioidergic and serotoninergic pathways. 27 Evidence for a possible alteration in dopaminergic control of prolactin in obesity comes indirectly from a study of weight loss in association with the normalisation of plasma prolactin in patients with prolactin secreting pituitary adenomas. 28 A clear relationship was seen between high prolactin levels and increased body mass: neither increased body weight nor recent weight gain could be attributed to tumoural mass effect on the central hypothalamic area.…”

Section: Prolactin Secretion In Obesitymentioning

confidence: 99%

Physiopathology of prolactin secretion in obesity

Kopelman

2000

Int J Obes

View full text Add to dashboard Cite

In many species prolactin is of biological importance and has a major role in determining the deposition and mobilization of fat. In human physiology, outside pregancy, prolactin secretion is altered by increasing body weight in both children and adults. Prolactin in this circumstance appears to be marker of hypothalamic ± pituitary function: the prolactin response to insulin-hypoglycaemia, thyrotrophin releasing hormone stimulation and other stimulatory factors may be diminished. In addition, obesity alters the 24 h spontaneous release of prolactin with a generalised dampening of release. A number of explanations have been given as possible causes for these alterations, but it seems likely that they re¯ect obesity per se and are associated with hyperinsulinaemia. Weight reduction, with accompanying decrease in plasma insulin levels, leads to a normalization of prolactin responses in most, but not all, circumstances. To date, no molecular basis has been identi®ed which links prolactin with increasing body fatness, weight and appetite: new data suggests a possible link in obese men between fasting plasma prolactin and leptin concentrations.

show abstract

“…Dexfenfluramine is a more potent stimulus for PRL secretion than l-fenfluramine (453), and amphetamine had no significant effect. The rise in PRL produced by dexfenfluramine can be attenuated in lean women by naloxone, an opioid antagonist, but in obese women naloxone had no effect on the rise in PRL (454). In contrast, the rise in ACTH and cortisol after naloxone was significantly higher in obese than in lean women and 7 days of treatment with dexfenfluramine attenuated the response to naloxone (455).…”

Section: December 1999 Drug Treatment Of Obesity 821mentioning

confidence: 68%